Skip to main content

AXIM® Biotechnologies Appoints Dr. Alim Seit-Nebi as Chief Technology Officer of Subsidiary Sapphire Biotech

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today it has appointed Dr. Alim Seit-Nebi as the Chief Technology Officer (“CTO”) of its subsidiary Sapphire Biotech, Inc. (“Sapphire”).
Dr. Seit-Nebi is an expert in a broad range of biochemical, genetic, molecular, and cellular biology methods with detailed knowledge of signaling pathways in inflammation, oncogenesis, and cell stress response. Prior to becoming Sapphire’s CTO, Dr. Seit-Nebi dedicated over a decade to lead the development and production of antibodies, recombinant proteins, biomarkers, and immunoassays for diagnostic and therapeutic applications.“We are humbled to have a well-established biomedical expert such as Dr. Seit-Nebi so deeply involved in the mission of Sapphire Biotech,” said AXIM® Biotech CEO John W. Huemoeller II. “His knowledge and experience fill an essential role in our team.”At Sapphire, Dr. Seit-Nebi will lead the development and implementation of new antibody and protein-based technologies in diagnostics and therapeutics. He received a Doctorate degree in Molecular Biology from the Engelhardt Institute of Molecular Biology in Moscow, Russia, and continued his research in Immunology and Molecular Biology Departments of The Scripps Research Institute in La Jolla, California.“I am inspired by Sapphire’s mission to deliver innovative solutions for global cancer care, and I feel fortunate to become part of the team thriving to achieve such an ambitious goal,” said Dr. Seit-Nebi, Chief Technology Officer of Sapphire Biotech.For more information about AXIM, please visit www.aximbiotech.com.About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses and new cannabinoid molecules for oncological therapeutics.Currently, Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. For more information, please visit www.AXIMBiotech.com.FORWARD-LOOKING DISCLAIMER
 This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM® Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.comCorporate Contact Info:
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-999-0920Investor Relations Contact:
investors@aximbiotech.com
888-759-0844

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.